We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ALK Abello AS | TG:4AJ0 | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.20 | -0.99% | 20.00 | 19.97 | 20.02 | 20.10 | 20.00 | 20.10 | 591 | 12:41:36 |
From Jan 2025 to Jan 2025
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF):
to be held at ALK
Bøge Allé 1
2970 Hørsholm, Denmark
Written requests to have specific business
transacted at the AGM will be included in the
agenda if received by the company on
29 January 2025 at the latest
(may be emailed to investor@alk.net)
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Maiken Riise Andersen, tel. +45 5054 1434
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,900 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.
Attachment
1 Year ALK Abello AS Chart |
1 Month ALK Abello AS Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
